Oxis

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxis

Quick Facts

Property Description
Active Ingredient Formoterol (Formoterol fumarate dihydrate)
Form Inhalation powder (e.g., Turbuhaler), Pressurized inhalation solution
Pharmacological Class Long-acting beta-agonist (LABA); Selective beta2-adrenoceptor agonist
Common Use Maintenance therapy for constricted airways
Origin Synthetic

What Type of Medicine is Oxis? (Classification and Composition)

Oxis is a synthetic prescription pharmaceutical preparation whose active ingredient is Formoterol, specifically Formoterol fumarate dihydrate. Formoterol is classified as a selective beta2-adrenoceptor agonist, positioning it within the Long-Acting Beta-Agonist (LABA) class of medications. This classification reflects its role in the prolonged management of chronic airflow limitation.

Oxis is a single-ingredient product, containing Formoterol as its sole active pharmaceutical component. This focused formulation provides physicians with the flexibility to manage the bronchodilator component separately from other concurrent treatments. The formulation provides a specific, long-acting effect on respiratory smooth muscles.

Oxis Form and General Purpose (Delivery and Therapeutic Goal)

The medication is formulated for inhaled therapy and is delivered via the pulmonary route, typically as an inhalation powder in a specialized device. The primary general purpose of Oxis is to provide sustained control over the muscles surrounding the airways by establishing a consistent bronchodilation effect.

This action means the drug helps keep the airways open over many hours, reducing the chance of them tightening and providing long-term, regular control of breathing difficulties. Its typical use involves a regular, scheduled application, establishing a protective effect against muscle constriction in the airways as part of a chronic maintenance treatment plan.

Regulatory References

  1. NIH: Bronchodilators (StatPearls)

What side effects are possible with Oxis?

Possible Side Effects and Safety Information

The safety profile for Oxis, which contains Formoterol, is formally detailed in regulatory documents by classifying potential effects according to frequency and the body system affected. Adverse reactions are grouped across several System-Organ Classes, including the Nervous System (e.g., headache, dizziness, tremor), Cardiac Disorders (e.g., palpitations, tachycardia), and Metabolism and Nutrition (e.g., hypokalemia).

Adverse Reaction Classifications

Classification Examples of Officially Documented Effects
Common Headache, tremor, insomnia, dizziness.
Uncommon Palpitations, tachycardia, muscle cramps.

Serious Adverse Reactions and Safety Constraints

Official labels document critical safety warnings. One serious adverse reaction is paradoxical bronchospasm, a potentially life-threatening reaction characterized by immediate worsening of breathing after inhalation. A primary regulatory constraint involves the risk of Serious Asthma-Related Events (including death and hospitalization) when the medicine is used as monotherapy for persistent asthma, requiring its use only in combination with an inhaled corticosteroid.

Specific safety considerations are noted for certain conditions, including pre-existing cardiovascular disorders, seizure disorders, and diabetes mellitus. The label also documents potential metabolic effects, such as hypokalemia (low blood potassium) and hyperglycemia (increased blood glucose). Use in patients with severe hepatic impairment requires particular caution due to potentially increased drug exposure. The risk of cardiac effects may be more prominent at the initiation of treatment or following dose increases.

Overdose and Emergency Response

Overdose and when to seek help

The overdose profile for Formoterol (Oxis) is established in regulatory documents based on the effects of excessive sympathomimetic stimulation.

Documented Overdose Presentations
Cardiovascular: Tachycardia, palpitations, angina, and cardiac arrhythmias.
Neurological: Tremor, nervousness, headache, and severe cases involving convulsions (seizures).
Metabolic: Hypokalemia (low serum potassium) and hyperglycemia (high blood glucose).

Excessive use of inhaled sympathomimetics, or use in conjunction with other long-acting beta-agonists, can result in clinically significant cardiovascular effects and fatalities have been reported. A life-threatening paradoxical bronchospasm can also occur and requires immediate intervention. Regulatory information notes that exposure may be increased in patients with severe hepatic impairment.

Immediate Actions and Monitoring Requirements:

Upon suspicion of overdose, the medication must be discontinued immediately. Urgent medical help must be sought if symptoms are present. Seek emergency medical attention or call 911 (emergency services) immediately if the affected person has trouble breathing, seizures, or loss of consciousness.

Management is symptomatic and supportive. Continuous observation and monitoring of cardiac function is required due to the risk of arrhythmias. Additionally, monitoring of serum potassium and blood glucose levels is necessary to manage documented metabolic abnormalities.

Therapeutic Uses of Oxis

What Oxis Treats: Main Uses and Benefits

Formoterol, the active ingredient in Oxis, is commonly used as a long-acting bronchodilator for maintenance treatment to support stability in chronic respiratory conditions. The medication supports patients with conditions like Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema, by easing symptoms that create noticeable physiological strain.

The medication is relevant for easing symptom clusters that may become intense or disruptive, specifically wheezing, chronic cough, and the feeling of chest tightness or shortness of breath. It is commonly used for the long-term management of both COPD and persistent asthma in adults and adolescents, and is considered relevant for managing symptoms associated with acute or episodic changes, such as exercise-induced bronchospasm.

This scheduled, continuous use contributes to easing the overall symptom load associated with recurrent manifestations. The primary intent of this therapy is to provide continuous, supportive relief during symptomatic periods. This provides support that helps patients cope more steadily with symptom fluctuations.


Quick Fact: Relief for Recurrent Breathing Difficulties

Symptom Domain Relief Provided
Airflow Impairment Supports functional stability and helps ease discomfort.
Nocturnal Symptoms Contributes to supporting stability during sleep periods.
Exertion Triggers May assist with symptoms that interfere with physical activity.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Oxis (Formoterol) is a maintenance medication with specific eligibility criteria defined by regulatory authorities. Its use is generally permitted for Adults and Adolescents (ge 12 years) for chronic respiratory conditions.

Contraindications and Restrictions

Classification Rule (Official Labeling)
Absolute Contraindication Patients with known hypersensitivity to Formoterol or any excipients (e.g., milk proteins).
Asthma Monotherapy Must not be used alone for asthma; Formoterol must be combined with an Inhaled Corticosteroid (ICS) for asthma treatment.
Acute Status Not indicated for the relief of acute bronchospasm or to treat acutely deteriorating COPD or asthma.

Conditional Use and Limitations

Use requires caution and monitoring in patients with certain conditions, including severe cardiovascular disorders (e.g., tachyarrhythmias, severe heart failure), thyrotoxicosis, diabetes mellitus, and prolonged QTc-interval.

  • Pediatric Use: Use is not recommended in children under 6 years of age due to insufficient data on safety and efficacy.
  • Pregnancy/Lactation: Use is conditional and requires a benefit-risk assessment. Formoterol may potentially interfere with uterine contractility.

What should I know about interactions with other medicines?

Interactions with other medicines and products are defined by regulatory labeling based on documented pharmacodynamic and pharmacokinetic patterns.

Contraindicated and Restricted Combinations

Co-administration with other Long-Acting beta2-Agonists (LABAs) is strictly prohibited due to the risk of overdose and excessive systemic exposure. beta-Adrenergic Blocking Agents, including eye drops, are generally not given concurrently as they may inhibit Formoterol’s bronchodilating effect. This interaction may require compelling therapeutic justification if the combination is deemed necessary.


Pharmacodynamic Interaction Risks

Oxis carries a documented risk of serious pharmacodynamic interaction when used with certain drug classes. Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and other Drugs that Prolong the QTc-Interval require extreme caution as they may potentiate Formoterol's effects on the cardiovascular system, increasing the risk of adverse cardiac events. Further pharmacodynamic interactions exist with Xanthine Derivatives, Steroids, and non-potassium sparing Diuretics, as co-administration may potentiate the rare effect of hypokalemia and associated ECG changes.


Administration Timing and Population Note

The regulatory profile mandates a specific administration rule for co-existing respiratory therapy: the regular daily use of inhaled Short-Acting beta2-Agonists (SABAs) must be discontinued, with use restricted only to acute symptomatic relief. Furthermore, official labeling includes a population-specific pharmacokinetic caution, noting that in patients with severe hepatic impairment, systemic exposure to Formoterol may increase, potentially elevating the risk of drug effects.

Mechanism of Action

Oxis (Formoterol) exerts its function through specific pharmacodynamic actions, resulting in a sustained alteration to smooth muscle tone in the airways. The mechanism is focused on adjusting the biological signaling that governs smooth muscle contraction.

Targeting and Activating Airway Relaxation Receptors

The drug's primary mechanism involves acting as a full agonist at the beta2-adrenoceptors, which are numerous on the bronchial smooth muscle cells. This targeted activation initiates a specific signaling cascade that results in muscle relaxation. The high lipophilicity of Formoterol allows it to partition into the cell membrane, forming a depot which supports the mechanism's activity for an extended duration.

Modulating the Intracellular cAMP Signaling Cascade

Binding to the beta2-adrenoceptor triggers the activation of Adenylyl Cyclase, which rapidly increases levels of the secondary messenger, cyclic AMP (cAMP). This cAMP-driven cascade ultimately leads to the reduction of available intracellular calcium ( Ca^2+) necessary for muscle contraction. The resulting inhibition of the contractile apparatus causes the physical relaxation of the airway smooth muscle, which leads to bronchodilation and a reduction in mechanical airflow resistance.

Mechanism Limitations: Spasm vs. Inflammation

While the mechanism successfully induces muscle relaxation, it provides minimal modulation of underlying chronic inflammatory processes in the airways, possessing a primarily mechanical activity. Additionally, prolonged and isolated exposure can lead to receptor desensitization, a mechanistic constraint where the target receptors become less responsive over time.

Dosage and Administration Information

The administration of Oxis centers on the oral inhalation route via two primary formulations: a dry inhalation powder or an inhalation solution for nebulization. For most maintenance regimens, the medication is administered on a fixed schedule, typically twice daily, with doses spaced approximately 12 hours apart.


Official Dosing and Frequency Patterns

The inhalation powder is commonly available in metered doses of 6 and 12 micrograms (mcg). The standard adult maintenance dose for chronic respiratory conditions is typically 6 to 12 mcg twice daily. Dosing for the inhalation solution is standardized at 20 mcg administered twice daily. Regardless of the form, the total amount of medicine administered in a 24-hour period must adhere to the established maximum daily dose, which generally does not exceed 48 mcg (metered dose equivalent) in total for regular use.


Administration Protocol and Special Groups

Proper administration technique is mandatory for correct use. The powder form requires the user to execute a forceful and deep inhalation to draw the medicine into the lungs. Conversely, the inhalation solution must be administered using a standard jet nebulizer and should not be mixed with any other medication in the nebulizer reservoir.

The drug is designated for long-term maintenance therapy, and doses must not be doubled to compensate for a missed dose. Specific parameters apply to younger populations: children aged 6 years and older with asthma may be administered a reduced daily dose, typically not exceeding 24 mcg per day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Oxis (Formoterol)


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

The research base for Oxis (Formoterol) in Chronic Obstructive Pulmonary Disease (COPD) is founded on a substantial collection of high-quality Randomized Controlled Trials (RCTs) and syntheses called meta-analyses. Research generally focused on adults with moderate-to-severe COPD, examining outcomes related to lung function measurements (such as FEV₁) and patient-reported outcomes describing perceived discomfort.

Studies conducted during periods of increased symptom activity documented that measured lung function parameters remained at similar levels over the observed follow-up periods, typically extending up to 12 months. Findings describe patterns observed in the studies related to changes in symptomatic scores. Research has also explored outcomes related to major endpoints like the frequency of flare-ups (exacerbations).

Evidence for Use in Persistent Asthma

Clinical trials and systematic reviews examining the use of Formoterol for persistent asthma have focused on adults and adolescents (typically age ≥ 12). In this condition, Formoterol is used only as an add-on treatment and is always studied in combination with a daily inhaled corticosteroid (ICS). Key outcomes monitored were overall asthma control measures and the rate of severe asthma exacerbations.

Large-scale analyses have described patterns indicating that the combined regimen was associated with the reported asthma control metrics in a higher proportion of participants compared to ICS alone. It is critical to note that official regulatory guidance prohibits the use of Formoterol monotherapy (Oxis without an ICS) for asthma. This restriction is based on regulatory guidance prohibiting the use of Formoterol monotherapy for this condition.


What is Still Uncertain About the Research

The key limitations in the evidence base include the requirement for combination therapy for asthma. Data for certain groups, particularly very young children and patients with specific comorbid conditions, remain insufficient. Additionally, while long-term RCTs provided up to one year of follow-up, there is limited information for understanding the sustained outcomes over many years.

Key Studies & References

  1. Long-acting β-agonists: use in chronic obstructive pulmonary disease (MHRA Safety Update)
  2. Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NICE Guideline NG115 Evidence Review)

Frequently Asked Questions (FAQ)

Common questions about Oxis (FAQ)


Q: Is Oxis the same type of medicine as [similar sounding/competitor drug]?

A: Oxis contains the active ingredient Formoterol, which is classified as a Long-Acting Beta-Agonist (LABA). This classification is based on its specific function and sustained duration of action, positioning it within the same general class as other long-acting medications used for chronic airway management.

Q: What kind of side effects are people worried about with Oxis?

A: Official safety documents describe common effects such as headache, tremor, and dizziness. Regulatory information also documents the potential for effects on the cardiovascular system, such as a fast or racing heartbeat (palpitations), and metabolic changes like low blood potassium (hypokalemia).

Q: How long does the effect of Oxis last?

A: The medication is typically administered on a twice-daily schedule. The drug is formulated to provide a sustained bronchodilating effect over many hours.

Q: Are there any major food or drink restrictions with Oxis?

A: Regulatory documents defining drug interactions do not typically list specific food or beverage restrictions for Oxis. However, patients are generally advised to inform their prescribing physician about all products and substances they consume to ensure complete awareness.

Q: Can Oxis make you feel dizzy or lightheaded?

A: Yes, dizziness is listed as a common documented side effect in official product information. This is a nervous system effect that can be experienced by some users. Other common effects in this category include headache and difficulty sleeping (insomnia).

Q: Is it normal to feel [mild, common side effect] when first starting Oxis?

A: Official safety constraints note that the risk of certain effects, particularly those related to the heart, may be more noticeable at the initiation of treatment or following a dose increase.

Q: Does Oxis cause changes in appetite?

A: Official regulatory information lists loss of appetite as a potential, though rare, adverse reaction to Formoterol. This is not listed among the more common side effects.

Q: Can I take Oxis on an empty stomach?

A: Oxis is designed for inhalation, meaning the medicine is delivered directly to the lungs, bypassing the digestive system. Because of the route of administration, regulatory documents defining the schedule do not typically specify taking the drug in relation to meals or on an empty stomach.

Q: What should I know about stopping Oxis?

A: Oxis is intended for long-term maintenance therapy to keep airways open consistently. Regulatory guidance states that treatment should not be stopped suddenly.

Q: Has Oxis been studied for long-term safety?

A: Research has included randomized controlled trials that have provided long-term follow-up data for periods extending up to one year. Official labels note, however, that there is limited information available regarding the sustained outcomes and safety over many years of treatment.

Q: Is it described as a 'first-line' or 'second-line' treatment?

A: For the treatment of asthma, Formoterol (Oxis) is described in official documents as an add-on treatment. This means it must be used in combination with an inhaled corticosteroid (ICS) and is not intended to be used as a stand-alone, or monotherapy, treatment for persistent asthma.

Q: Do you need a special prescription or monitoring for Oxis?

A: Oxis is a prescription-only medicine (Rx-only). The official label documents that increased monitoring is noted for specific patient populations, such as those with diabetes (blood glucose) or patients at risk of hypokalemia (blood potassium levels).

Q: What is the general difference between Oxis and other common treatments for this condition?

A: Oxis contains Formoterol, a Long-Acting Beta-Agonist (LABA). This makes its primary action providing a consistent opening of the airways that lasts up to 12 hours. Other treatments for the same condition may be in different drug classes with distinct durations or functions.

Q: Is Oxis considered a 'new' drug?

A: While the specific formulation may vary, the active ingredient in Oxis, Formoterol, has been in continuous medical use globally since the late 1990s.

Q: Can Oxis affect my sleep?

A: Yes, official safety documents list insomnia (difficulty falling or staying asleep) as a common side effect. Other sleep disturbances are also documented as uncommon effects.

Q: What happens if I miss a scheduled time for Oxis?

A: Regulatory guidance emphasizes that doses must not be doubled to try to compensate for a missed dose.

Q: Is there a risk of dependency or addiction with Oxis?

A: The active ingredient in Oxis, Formoterol, is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar bodies globally.

Q: Can Oxis affect fertility or pregnancy planning?

A: Use during pregnancy is conditional and requires an official benefit-risk assessment due to its potential to interfere with uterine contractility. There is typically no explicit human data on fertility documented in the product labels.

Q: Can I take Oxis with my daily vitamin regimen?

A: Regulatory documents primarily focus on interactions with other prescription drugs. As a general caution, patients are advised to inform their physician about all other products they use, including vitamins, herbal supplements, and over-the-counter medications.

Q: Is Oxis available as a generic medicine?

A: The active ingredient, Formoterol, is available as a generic medication in many regions after patent exclusivity ended.

Q: Does Oxis require special storage conditions?

A: The product must be stored in a cool, dry place where the temperature stays below 30°C. To maintain the stability of the powder, the device's cap must be kept tightly closed, protecting the medicine from moisture.

Q: Are there any long-term health concerns associated with Oxis?

A: Official safety documents emphasize caution in patients with pre-existing cardiovascular disorders and note the risk of serious asthma-related events when used alone for asthma. While studies provide data up to a year, sustained outcomes over many years have limited regulatory information.

Q: Can I drive or operate machinery while using Oxis?

A: Official patient information states that Oxis is not likely to affect the ability to drive or use tools or machines. However, the information also documents that dizziness and tremor are common side effects, which could potentially affect performance.

Q: Is Oxis a controlled substance?

A: No, the active ingredient in Oxis, Formoterol, is not listed as a controlled substance in official drug schedules.

Q: Can Oxis be crushed or split?

A: Oxis is formulated as an inhalation powder or solution for specialized devices. It must be administered using the required inhalation technique or jet nebulizer. Regulatory documents do not address altering the medication by crushing or splitting it.

Q: Is Oxis a preventative medicine or a treatment?

A: Oxis is described as a long-term maintenance treatment to provide sustained control over the airways. It is not indicated for the relief of sudden, acute breathing difficulties (bronchospasm).

How should Oxis be stored and disposed of?

Storage and Disposal Requirements for Oxis

The storage and disposal instructions for Oxis Turbohaler (formoterol fumarate dihydrate) are defined by regulatory authorities to ensure the stability of the inhalation powder and patient safety.


Official Storage Conditions

The product must be stored in a cool, dry place where the temperature stays below 30°C and should be kept out of the sight and reach of children. To maintain the stability of the dry powder, the device's cap must be kept tightly closed when not in use. Stability is linked directly to keeping the container properly sealed to protect the medicine from moisture.


Disposal Instructions

Official labeling generally states there are no special requirements for disposal. However, to prevent environmental contamination, unused or expired Oxis should not be thrown away in household waste or wastewater, but should be returned to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxis found in:

A-Z Index: